Trending...
- Alumi-Span Helps Customers Rebuild Old Docks!
- School Launches 250 Students International Service Trips - Gives $1M to Global Education
- Lawn Care Company Near South Lyon Shares Crabgrass-Busting Secrets
DETROIT, May 20, 2024 ~ The Barbara Ann Karmanos Cancer Institute has recently welcomed a new leader to their team. Dr. Wasif Saif, a world-renowned hematologist and oncologist, has joined the institute as the leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team (MDT). This appointment took effect on March 1, 2024.
In an interview, Dr. Saif expressed his excitement about joining Karmanos Cancer Institute, stating that it is a trailblazer in cancer research and has made significant contributions to new drug and therapy development. He also mentioned his eagerness to continue translational research at this NCI-Designated Comprehensive Cancer Center, with access to a diverse cancer population.
As the Phase 1 Clinical Trials MDT leader, Dr. Saif will be responsible for overseeing Phase 1 solid tumor investigations. This includes leading a team of physician co-investigators, non-physician providers, clinical personnel, and Clinical Trials Office staff. Karmanos' Phase 1 team currently oversees over 70 clinical trials at various stages of the protocol lifecycle.
More on Michimich.com
Dr. Saif's expertise in translational research and managing clinical trials makes him well-suited for this role. He will also work alongside Dr. Najeeb Al Hallak in leading the GI and Neuroendocrine Oncology MDT, which is made up of various specialists dedicated to researching and treating GI and neuroendocrine cancers.
Dr. Saif specializes in treating a wide range of cancers including anal, biliary, colon, carcinoid, esophagus, GIST, liver, pancreas, rectum, and stomach cancers. His research interests include anticancer drug development with a focus on pharmacokinetics and pharmacodynamics analysis, biomarker discovery, pharmacogenetics, epidemiology and disparity studies in GI cancers, and developing complementary and alternative medicines for cancer treatment.
Karmanos' president and CEO, Dr. Boris Pasche, expressed his confidence in Dr. Saif's leadership and vision for the Phase 1 Clinical Trials Program at Karmanos. He also believes that Dr. Saif's research interests in GI cancers will complement the institute's existing team.
Aside from his leadership roles, Dr. Saif also sees patients at Karmanos Cancer Center in Detroit and is a professor in the Department of Oncology at Wayne State University School of Medicine.
More on Michimich.com
Prior to joining Karmanos, Dr. Saif has held faculty positions at various prestigious institutions such as the University of Alabama at Birmingham, Yale University School of Medicine, Columbia University, and Tufts University School of Medicine. He has also served in executive roles at Northwell Health and Orlando Health.
Dr. Saif is a member of several professional organizations including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society of Medical Oncology (ESMO), Carcinoid Foundation, and American Society of Pharmacology and Experimental Therapeutics (ASPET). He has also been the principal investigator on over 75 clinical trials and has published over 650 scientific papers.
Dr. Saif received his medical degree from King Edward Medical College in Lahore, Pakistan, and completed his residency in internal medicine at the University of Connecticut School of Medicine. He then went on to complete fellowships in medical oncology and hematology at various institutions including the National Cancer Institute.
To learn more about Dr. Wasif Saif or to request an appointment for Phase 1 Clinical Trials, interested individuals can visit karmanos.org or call 1-800-KARMANOS.
In an interview, Dr. Saif expressed his excitement about joining Karmanos Cancer Institute, stating that it is a trailblazer in cancer research and has made significant contributions to new drug and therapy development. He also mentioned his eagerness to continue translational research at this NCI-Designated Comprehensive Cancer Center, with access to a diverse cancer population.
As the Phase 1 Clinical Trials MDT leader, Dr. Saif will be responsible for overseeing Phase 1 solid tumor investigations. This includes leading a team of physician co-investigators, non-physician providers, clinical personnel, and Clinical Trials Office staff. Karmanos' Phase 1 team currently oversees over 70 clinical trials at various stages of the protocol lifecycle.
More on Michimich.com
- Multi-Million Dollar Contracts and Key Partnerships for Cybersecurity Solutions in the Rapidly Growing Market Nearing $200 Billion Annually $CYCU
- Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
- Brookline Family Dentistry Updates Website URL for a Stronger Brand Identity
- Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
- Rosann Santos Ofrece el Programa Repensando el Síndrome del Impostor™
Dr. Saif's expertise in translational research and managing clinical trials makes him well-suited for this role. He will also work alongside Dr. Najeeb Al Hallak in leading the GI and Neuroendocrine Oncology MDT, which is made up of various specialists dedicated to researching and treating GI and neuroendocrine cancers.
Dr. Saif specializes in treating a wide range of cancers including anal, biliary, colon, carcinoid, esophagus, GIST, liver, pancreas, rectum, and stomach cancers. His research interests include anticancer drug development with a focus on pharmacokinetics and pharmacodynamics analysis, biomarker discovery, pharmacogenetics, epidemiology and disparity studies in GI cancers, and developing complementary and alternative medicines for cancer treatment.
Karmanos' president and CEO, Dr. Boris Pasche, expressed his confidence in Dr. Saif's leadership and vision for the Phase 1 Clinical Trials Program at Karmanos. He also believes that Dr. Saif's research interests in GI cancers will complement the institute's existing team.
Aside from his leadership roles, Dr. Saif also sees patients at Karmanos Cancer Center in Detroit and is a professor in the Department of Oncology at Wayne State University School of Medicine.
More on Michimich.com
- Criptlán Partners with Top Capital and Technology Teams to Drive the Future of the Digital Economy
- From Sea to the Site: The Evolution of the Shipping Container From the Water to the Worksite
- Inbound Lead Generation for Security Companies in 2025: The Key to Sustainable Growth
- C & C Heating & Air Conditioning celebrates National Women's History Month by encouraging women to join the skilled trades industry
- Frame Up Now Leverages Cyntexa and Salesforce to Fuel Their Operations & Power Up Lead Conversion
Prior to joining Karmanos, Dr. Saif has held faculty positions at various prestigious institutions such as the University of Alabama at Birmingham, Yale University School of Medicine, Columbia University, and Tufts University School of Medicine. He has also served in executive roles at Northwell Health and Orlando Health.
Dr. Saif is a member of several professional organizations including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society of Medical Oncology (ESMO), Carcinoid Foundation, and American Society of Pharmacology and Experimental Therapeutics (ASPET). He has also been the principal investigator on over 75 clinical trials and has published over 650 scientific papers.
Dr. Saif received his medical degree from King Edward Medical College in Lahore, Pakistan, and completed his residency in internal medicine at the University of Connecticut School of Medicine. He then went on to complete fellowships in medical oncology and hematology at various institutions including the National Cancer Institute.
To learn more about Dr. Wasif Saif or to request an appointment for Phase 1 Clinical Trials, interested individuals can visit karmanos.org or call 1-800-KARMANOS.
Filed Under: Business
0 Comments
Latest on Michimich.com
- STRETCHIT Announces it is Now Available to Millions of Employees on Wellhub, the Leader in Corporate Wellness
- The OpenSSL Corporation and The OpenSSL Foundation Announce the Formation of Technical Advisory Committees (TACs)
- Wilderness Construction Highlights the Benefits of Open-Concept Kitchens
- Roofman Expands Service Area to Provide Top-Quality Roofing Across Michigan
- Local Roofing Experts Share Essential Tips to Prepare Michigan Homes for Storm Season
- Uzoma Ra of We Do Marketing Services .com Named Local Business Person of the Year for 2025 in MI
- Sip, Savor, and Celebrate Earth Day on the Shawangunk Wine Trail - April 26-27, 2025
- Kintetsu International Launches Innovative Online Hotel Booking Platform
- Security & Compliance on Microsoft 365 Without the Overhead
- Liquid Technologies Announces the Launch of Liquid Studio v21 and Liquid XML Data Binder v21
- Qrybut Successfully Obtains SEC Certification, Bridging Traditional Finance and Digital Assets
- Glisn Launches Revolutionary Cognitive Training App to Combat the Modern Attention Crisis
- Portland's Evolve & Unite Festival Brings a Transformational Experience to the Pacific Northwest
- School Launches 250 Students International Service Trips - Gives $1M to Global Education
- "United Dumpster Rental Expands Affordable Waste Management Services Across Metro Detroit and Beyond
- Lawn Care Company Near South Lyon Shares Crabgrass-Busting Secrets
- Alumi-Span Helps Customers Rebuild Old Docks!
- DivX Unveils Enhanced Guide on Converting MOV to MP4 for Effortless Video Conversion
- SourceCode Expands AI Factory Offerings with Atlas AI Ignite at GTC 2025
- Karen Mueller Leads the Charge in Infection Prevention as SterileCare Drives Meaningful Change in Catheter Care